|
1
|
Fan XQ and Guo YJ: Apoptosis in oncology.
Cell Res. 11:1–7. 2001. View Article : Google Scholar
|
|
2
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Andera L: Signaling activated by the death
receptors of the TNFR family. Biomed Pap Med Fac Univ Palacky
Olomouc Czech Repub. 153:173–180. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim R, Emi M, Tanabe K, Uchida Y and Toge
T: The role of Fas ligand and transforming growth factor β in tumor
progression: molecular mechanisms of immune privilege via
Fas-mediated apoptosis and potential targets for cancer therapy.
Cancer. 100:2281–2291. 2004.
|
|
5
|
Reichmann E: The biological role of the
Fas/FasL system during tumor formation and progression. Semin
Cancer Biol. 12:309–315. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Randhawa SR, Chahine BG, Lowery-Nordberg
M, Cotelingam JD and Casillas AM: Underexpression and
overexpression of Fas and Fas ligand: a double-edged sword. Ann
Allergy Asthma Immunol. 104:286–292. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Whiteside TL: The role of death receptor
ligands in shaping tumor microenvironment. Immunol Invest.
36:25–46. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fulda S and Pervaiz S: Apoptosis signaling
in cancer stem cells. Int J Biochem Cell Biol. 42:31–38. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Houston A and O'Connell J: The Fas
signalling pathway and its role in the pathogenesis of cancer. Curr
Opin Pharmacol. 4:321–326. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wajant H: The Fas signaling pathway: more
than a paradigm. Science. 296:1635–1636. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang QR, Morris D and Manolios N:
Identification and characterization of polymorphisms in the
promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol.
34:577–582. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu J, Metz C, Xu X, Abe R, Gibson AW,
Edberg JC, Cooke J, Xie F, Cooper GS and Kimberly RP: A novel
polymorphic CAAT/enhancer-binding protein β element in the FasL
gene promoter alters Fas ligand expression: a candidate background
gene in African American systemic lupus erythematosus patients. J
Immunol. 170:132–138. 2003.PubMed/NCBI
|
|
13
|
Zhang Z, Qiu L, Wang M, Tong N, Li J and
Zhang Z: The FAS ligand promoter polymorphism, rs763110
(-844C>T), contributes to cancer susceptibility: evidence from
19 case-control studies. Eur J Hum Genet. 17:1294–1303. 2009.
|
|
14
|
Zhang Z, Xue H, Gong W, Wang M, Yuan L,
Han S and Zhang Z: FAS promoter polymorphisms and cancer risk: a
meta-analysis based on 34 case-control studies. Carcinogenesis.
30:487–493. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: the impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Keane MM, Ettenberg SA, Lowrey GA, Russell
EK and Lipkowitz S: Fas expression and function in normal and
malignant breast cell lines. Cancer Res. 56:4791–4798.
1996.PubMed/NCBI
|
|
17
|
Herrnring C, Reimer T, Jeschke U,
Makovitzky J, Krüger K, Gerber B, Kabelitz D and Friese K:
Expression of the apoptosis-inducing ligands FasL and TRAIL in
malignant and benign human breast tumors. Histochem Cell Biol.
113:189–194. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Müllauer L, Mosberger I, Grusch M, Rudas M
and Chott A: Fas ligand is expressed in normal breast epithelial
cells and is frequently up-regulated in breast cancer. J Pathol.
190:20–30. 2000.PubMed/NCBI
|
|
19
|
Sun T, Miao X, Zhang X, Tan W, Xiong P and
Lin D: Polymorphisms of death pathway genes FAS and FASL in
esophageal squamous-cell carcinoma. J Natl Cancer Inst.
96:1030–1036. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang X, Miao X, Sun T, Tan W, Qu S, Xiong
P, Zhou Y and Lin D: Functional polymorphisms in cell death pathway
genes FAS and FASL contribute to risk of lung cancer. J Med Genet.
42:479–484. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lai HC, Sytwu HK, Sun CA, Yu MH, Yu CP,
Liu HS, Chang CC and Chu TY: Single nucleotide polymorphism at Fas
promoter is associated with cervical carcinogenesis. Int J Cancer.
103:221–225. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu Y, Wen QJ, Yin Y, Lu XT, Pu SH, Tian
HP, Lou YF, Tang YN, Jiang X, Lu GS and Zhang J: FASLG polymorphism
is associated with cancer risk. Eur J Cancer. 45:2574–2578. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang LH, Ting SC, Chen CH, Tsai CC, Lung
O, Liu TC, Lee CW, Wang YY, Tsai CL and Lin YC: Polymorphisms in
the apoptosis-associated genes FAS and FASL and risk of oral cancer
and malignant potential of oral premalignant lesions in a Taiwanese
population. J Oral Pathol Med. 39:155–161. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kang S, Dong SM, Seo SS, Kim JW and Park
SY: FAS -1377 G/A polymorphism and the risk of lymph node
metastasis in cervical cancer. Cancer Genet Cytogenet. 180:1–5.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Qiu LX, Shi J, Yuan H, Jiang X, Xue K, Pan
HF, Li J and Zheng MH: FAS -1,377 G/A polymorphism is associated
with cancer susceptibility: evidence from 10,564 cases and 12,075
controls. Hum Genet. 125:431–435. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shimonishi T, Isse K, Shibata F, Aburatani
I, Tsuneyama K, Sabit H, Harada K, Miyazaki K and Nakanuma Y:
Up-regulation of fas ligand at early stages and down-regulation of
Fas at progressed stages of intrahepatic cholangiocarcinoma reflect
evasion from immune surveillance. Hepatology. 32:761–769. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang M, Sun T, Wang L, Yu D, Zhang X, Miao
X, Liu J, Zhao D, Li H, Tan W and Lin D: Functional variants in
cell death pathway genes and risk of pancreatic cancer. Clin Cancer
Res. 14:3230–3236. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhu J, Qin C, Wang M, Yan F, Ju X, Meng X,
Ding Q, Li P, Yang J, Cao Q, Zhang Z and Yin C: Functional
polymorphisms in cell death pathway genes and risk of renal cell
carcinoma. Mol Carcinog. 49:810–817. 2010.PubMed/NCBI
|
